Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4452826
Max Phase: Preclinical
Molecular Formula: C55H79FN3O8P
Molecular Weight: 960.22
Molecule Type: Unknown
Associated Items:
ID: ALA4452826
Max Phase: Preclinical
Molecular Formula: C55H79FN3O8P
Molecular Weight: 960.22
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOP(=O)(OCC)C(Nc1ccc(CC(=O)NCCCCNC(=O)[C@@]2(C)CC[C@]3(C)CC[C@]4(C)C(=CC(=O)[C@@H]5[C@@]6(C)CC[C@H](OC(C)=O)C(C)(C)[C@@H]6CC[C@]54C)[C@@H]3C2)cc1)c1ccc(F)cc1
Standard InChI: InChI=1S/C55H79FN3O8P/c1-11-65-68(64,66-12-2)48(38-17-19-39(56)20-18-38)59-40-21-15-37(16-22-40)33-46(62)57-31-13-14-32-58-49(63)52(7)28-27-51(6)29-30-54(9)41(42(51)35-52)34-43(61)47-53(8)25-24-45(67-36(3)60)50(4,5)44(53)23-26-55(47,54)10/h15-22,34,42,44-45,47-48,59H,11-14,23-33,35H2,1-10H3,(H,57,62)(H,58,63)/t42-,44-,45-,47+,48?,51+,52-,53-,54+,55+/m0/s1
Standard InChI Key: CNOZBHRBLIHYBI-CLYCFIOUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 960.22 | Molecular Weight (Monoisotopic): 959.5589 | AlogP: 11.67 | #Rotatable Bonds: 17 |
Polar Surface Area: 149.13 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.64 | CX Basic pKa: 0.25 | CX LogP: 9.88 | CX LogD: 9.88 |
Aromatic Rings: 2 | Heavy Atoms: 68 | QED Weighted: 0.08 | Np Likeness Score: 1.09 |
1. Jin L, Zhang B, Hua S, Ji M, Huang X, Huang R, Wang H.. (2018) Glycyrrhetinic acid derivatives containing aminophosphonate ester species as multidrug resistance reversers that block the NF-κB pathway and cell proliferation., 28 (23-24): [PMID:30528976] [10.1016/j.bmcl.2018.10.025] |
Source(1):